These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10079062)

  • 21. IgG replacement therapy, no size fits all.
    Bonilla FA
    Clin Immunol; 2011 May; 139(2):107-9. PubMed ID: 21420364
    [No Abstract]   [Full Text] [Related]  

  • 22. Adverse events associated with intravenous immunoglobulin therapy.
    Hamrock DJ
    Int Immunopharmacol; 2006 Apr; 6(4):535-42. PubMed ID: 16504916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The new domestic immunoglobulin G gabriglobin in complex therapy of immunodeficiency states and infectious pathology].
    Pas'ko VG; Latysheva TV; Nikiforov VV; Mostovskaia EV; Denisov AK; Kondrashin IuI
    Voen Med Zh; 2006 Jul; 327(7):40-2. PubMed ID: 16977880
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety and patient acceptability of intravenous immune globulin in 10% maltose.
    Ochs HD; Buckley RH; Pirofsky B; Fischer SH; Rousell RH; Anderson CJ; Wedgwood RJ
    Lancet; 1980 Nov; 2(8205):1158-9. PubMed ID: 6107768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
    Wasserman RL; Melamed I; Stein MR; Gupta S; Puck J; Engl W; Leibl H; McCoy B; Empson VG; Gelmont D; Schiff RI;
    J Allergy Clin Immunol; 2012 Oct; 130(4):951-7.e11. PubMed ID: 22846381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of immune deficient neuropathies with intravenous polyvalent immunoglobulins. An open study of 16 cases].
    Hoang-Xuan K; Léger JM; Ben Younes-Chennoufi A; Saidi H; Bouche P; Baumann N; Brunet P
    Rev Neurol (Paris); 1993; 149(6-7):385-92. PubMed ID: 8303157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of intravenous immunoglobulin G (IVIG).
    Looney RJ; Huggins J
    Best Pract Res Clin Haematol; 2006; 19(1):3-25. PubMed ID: 16377538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety considerations in IGIV utilization.
    Siegel J
    Int Immunopharmacol; 2006 Apr; 6(4):523-7. PubMed ID: 16504914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins.
    Stein MR
    Postgrad Med; 2010 Sep; 122(5):176-84. PubMed ID: 20861601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Intravenous immunoglobulins in hematologic therapy].
    Giovanelli E
    Clin Ter; 1992 Sep; 141(9 Pt 2):69-73. PubMed ID: 1468201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process.
    Teschner W; Butterweck HA; Auer W; Muchitsch EM; Weber A; Liu SL; Wah PS; Schwarz HP
    Vox Sang; 2007 Jan; 92(1):42-55. PubMed ID: 17181590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Regulation of autoreactivity by the idiotypic network and therapeutic modulation of autoimmunity by polyvalent intravenous immunoglobulins (IgIV)].
    Lacroix-Desmazes S; Kaveri S; Kazatchkine MD
    Rev Neurol (Paris); 1996 May; 152(5):349-54. PubMed ID: 8881428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous immune globulins. A review of their uses in selected immunodeficiency and autoimmune diseases.
    Pirofsky B; Kinzey DM
    Drugs; 1992 Jan; 43(1):6-14. PubMed ID: 1372861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Giving intravenous immunoglobulin.
    Scherf R; White-Reid K
    RN; 2008 Jan; 71(1):29-34; quiz 35. PubMed ID: 18271361
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.
    Roifman CM; Schroeder H; Berger M; Sorensen R; Ballow M; Buckley RH; Gewurz A; Korenblat P; Sussman G; Lemm G
    Int Immunopharmacol; 2003 Sep; 3(9):1325-33. PubMed ID: 12890430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous immune globulin for multiple sclerosis.
    Tecnologica MAP Suppl; 1998 Aug; ():3-5. PubMed ID: 10342975
    [No Abstract]   [Full Text] [Related]  

  • 37. IGIV in neurology--evidence and recommendations.
    Bril V; Allenby K; Midroni G; O'Connor PW; Vajsar J
    Can J Neurol Sci; 1999 May; 26(2):139-52. PubMed ID: 10352875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients.
    Schroeder HW; Dougherty CJ
    Infection; 2012 Dec; 40(6):601-11. PubMed ID: 22968971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous immune globulin for recurrent fetal loss.
    Tecnologica; 1995 Nov; ():7-8. PubMed ID: 10168306
    [No Abstract]   [Full Text] [Related]  

  • 40. Consensus conference evaluates key issues concerning use of intravenous immune globulin.
    Clin Pharm; 1990 Jul; 9(7):489, 492-3. PubMed ID: 2198122
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.